Anti-Rat CXCL1 – Biotin

Purified Recombinant Rat CXCL1 (Accession # P14095)

This biotinylated antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 50 µg of bovine serum albumin per µg of antibody with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized, biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted bioin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Goat Anti-Rat CXCL1 recognizes Rat CXCL1. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

Chemokine (C-X-C motif) ligand 1 (CXCL1) is a small cytokine with mitogenic properties belonging to the CXC chemokine family that was previously called GRO1 oncogene, GROα, KC, Neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-α).¹ CXCL1 is expressed by macrophages, neutrophils and epithelial cells.² CXCL1 plays a role in spinal cord development by inhibiting the migration of oligodendrocyte precursors and is involved in the processes of angiogenesis, inflammation, wound healing.^3,4

1. Sager, R. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87: 7732
2. Grotendorst, GR. et al. (1990) Mol. Cell. Biol. 10: 5596
3. Miller, RH. et al. (2002) Cell 110: 373
4. Richmond, A. et al. (2000) J. Invest. Dermatol. 115: 234